{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Alzheimer+Disease+6",
    "query": {
      "condition": "Alzheimer Disease 6"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 14,
    "total_pages": 2,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Alzheimer+Disease+6&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-05-22T09:05:36.718Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00483028",
      "title": "A Randomized, Placebo-Controlled Trial to Examine the Efficacy of Oral Donepezil in Subjects With MCI",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Alzheimer's Disease"
      ],
      "interventions": [
        {
          "name": "donezepil (Aricept)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "55 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "55 Years to 90 Years"
      },
      "enrollment_count": 38,
      "start_date": "2004-06",
      "completion_date": "2007-01",
      "has_results": false,
      "last_update_posted_date": "2008-02-05",
      "last_synced_at": "2026-05-22T09:05:36.718Z",
      "location_count": 2,
      "location_summary": "New Haven, Connecticut • Albany, New York",
      "locations": [
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Albany",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00483028"
    },
    {
      "nct_id": "NCT00375557",
      "title": "Safety and Efficacy of Divalproex and Quetiapine in Elderly Alzheimer's Dementia Patients",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Alzheimer's Disease",
        "Dementia",
        "Behavioral Symptoms"
      ],
      "interventions": [
        {
          "name": "Divalproex ER",
          "type": "DRUG"
        },
        {
          "name": "Quetiapine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Cincinnati",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "55 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "55 Years to 85 Years"
      },
      "enrollment_count": 0,
      "start_date": "2006-10",
      "completion_date": "2007-09",
      "has_results": false,
      "last_update_posted_date": "2015-05-27",
      "last_synced_at": "2026-05-22T09:05:36.718Z",
      "location_count": 1,
      "location_summary": "Cincinnati, Ohio",
      "locations": [
        {
          "city": "Cincinnati",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00375557"
    },
    {
      "nct_id": "NCT00277810",
      "title": "Study Evaluating the Safety, Tolerability, and Efficacy of Lecozotan SR in Outpatients With Alzheimer's Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Alzheimer Disease"
      ],
      "interventions": [
        {
          "name": "lecozotan SR (SRA-333)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 250,
      "start_date": "2006-03",
      "completion_date": "2008-06",
      "has_results": false,
      "last_update_posted_date": "2020-07-07",
      "last_synced_at": "2026-05-22T09:05:36.718Z",
      "location_count": 33,
      "location_summary": "Phoenix, Arizona • Tucson, Arizona • Costa Mesa, California + 30 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Costa Mesa",
          "state": "California"
        },
        {
          "city": "Fresno",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00277810"
    },
    {
      "nct_id": "NCT03030105",
      "title": "Study to Evaluate the Effects of BPN14770 on Scopolamine-induced Cognitive Impairment in Healthy Volunteers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Alzheimer Disease"
      ],
      "interventions": [
        {
          "name": "BPN14770",
          "type": "DRUG"
        },
        {
          "name": "BPN14770 placebo",
          "type": "DRUG"
        },
        {
          "name": "Donepezil",
          "type": "DRUG"
        },
        {
          "name": "Donepezil placebo",
          "type": "DRUG"
        },
        {
          "name": "Scopolamine 0.6 MG/ML",
          "type": "DRUG"
        },
        {
          "name": "Scopolamine placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Tetra Discovery Partners",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 38,
      "start_date": "2017-01",
      "completion_date": "2017-06",
      "has_results": false,
      "last_update_posted_date": "2018-10-16",
      "last_synced_at": "2026-05-22T09:05:36.718Z",
      "location_count": 1,
      "location_summary": "Austin, Texas",
      "locations": [
        {
          "city": "Austin",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03030105"
    },
    {
      "nct_id": "NCT05637801",
      "title": "A Pivotal Study of Sensory Stimulation in Alzheimer's Disease (HOPE Study)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Alzheimer Disease",
        "Alzheimer Disease 1",
        "Alzheimer Disease 2",
        "Alzheimer Disease 3",
        "Alzheimer Disease, Early Onset",
        "Alzheimer Disease, Late Onset",
        "Alzheimer Disease 9",
        "Alzheimer Disease 4",
        "Alzheimer Disease 7",
        "Alzheimer Disease 17",
        "Alzheimer's Dementia Late Onset",
        "Alzheimer Disease 5",
        "Alzheimer Disease 6",
        "Alzheimer Disease 8",
        "Alzheimer Disease 10",
        "Alzheimer Disease 11",
        "Alzheimer Disease 12",
        "Alzheimer Disease 13",
        "Alzheimer Disease 14",
        "Alzheimer Disease 15",
        "Alzheimer Disease 16",
        "Alzheimer Disease 18",
        "Alzheimer Disease 19",
        "Dementia",
        "Dementia Alzheimers",
        "Dementia, Mild",
        "Dementia of Alzheimer Type",
        "Dementia Moderate",
        "Dementia Senile",
        "Mild Cognitive Impairment",
        "Mild Dementia",
        "MCI",
        "Cognitive Impairment",
        "Cognitive Decline",
        "Cognitive Impairment, Mild"
      ],
      "interventions": [
        {
          "name": "Spectris™ AD - Active",
          "type": "DEVICE"
        },
        {
          "name": "Spectris™ AD - Sham",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Cognito Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "50 Years to 90 Years"
      },
      "enrollment_count": 670,
      "start_date": "2022-12-13",
      "completion_date": "2026-07",
      "has_results": false,
      "last_update_posted_date": "2026-05-05",
      "last_synced_at": "2026-05-22T09:05:36.718Z",
      "location_count": 68,
      "location_summary": "Gilbert, Arizona • Phoenix, Arizona • Sun City, Arizona + 62 more",
      "locations": [
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Sun City",
          "state": "Arizona"
        },
        {
          "city": "Anaheim",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05637801"
    },
    {
      "nct_id": "NCT04100889",
      "title": "A Non-Interventional Pilot Study to Explore the Role of Gut Flora in Alzheimer's Disease",
      "overall_status": "WITHDRAWN",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Alzheimer Disease",
        "Alzheimer Disease 1",
        "Alzheimer Disease 2",
        "Alzheimer Disease 3",
        "Alzheimer Disease 4",
        "Alzheimer Disease 5",
        "Alzheimer Disease 6",
        "Alzheimer Disease 7",
        "Alzheimer Disease 8",
        "Alzheimer Disease 9, Late-Onset",
        "Alzheimer Disease 10",
        "Alzheimer Disease 11",
        "Alzheimer Disease 12",
        "Alzheimer Disease 13",
        "Alzheimer Disease 14",
        "Alzheimer Disease 15",
        "Alzheimer Disease 16",
        "Alzheimer Disease 17",
        "Alzheimer Disease 18",
        "Alzheimer Disease 19",
        "Alzheimer Disease, Early Onset",
        "Alzheimer Disease, Late Onset",
        "Alzheimer Disease Focal"
      ],
      "interventions": [
        {
          "name": "No Intervention",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "ProgenaBiome",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2020-03-02",
      "completion_date": "2030-07",
      "has_results": false,
      "last_update_posted_date": "2025-06-05",
      "last_synced_at": "2026-05-22T09:05:36.718Z",
      "location_count": 1,
      "location_summary": "Ventura, California",
      "locations": [
        {
          "city": "Ventura",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04100889"
    },
    {
      "nct_id": "NCT06810960",
      "title": "A Postmarketing Study of LEQEMBI in South Korean Participants With Alzheimer's Disease",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Alzheimer's Disease"
      ],
      "interventions": [
        {
          "name": "No Intervention",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Eisai Korea Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "19 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "19 Years and older"
      },
      "enrollment_count": 3000,
      "start_date": "2025-02-24",
      "completion_date": "2029-09-30",
      "has_results": false,
      "last_update_posted_date": "2026-04-21",
      "last_synced_at": "2026-05-22T09:05:36.718Z",
      "location_count": 1,
      "location_summary": "Nutley, New Jersey",
      "locations": [
        {
          "city": "Nutley",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06810960"
    },
    {
      "nct_id": "NCT01522404",
      "title": "Effects of Atomoxetine in Mild Cognitive Impairment",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Mild Cognitive Impairment"
      ],
      "interventions": [
        {
          "name": "Atomoxetine",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Emory University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "50 Years to 90 Years"
      },
      "enrollment_count": 39,
      "start_date": "2012-03",
      "completion_date": "2018-06-30",
      "has_results": true,
      "last_update_posted_date": "2019-07-23",
      "last_synced_at": "2026-05-22T09:05:36.718Z",
      "location_count": 1,
      "location_summary": "Atlanta, Georgia",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01522404"
    },
    {
      "nct_id": "NCT01883648",
      "title": "Study to Evaluate Coconut Oil for Alzheimer's Disease",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Alzheimer's Disease"
      ],
      "interventions": [
        {
          "name": "Coconut Oil Beverage",
          "type": "DRUG"
        },
        {
          "name": "Placebo Beverage",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "University of South Florida",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "55 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "55 Years to 90 Years"
      },
      "enrollment_count": 21,
      "start_date": "2013-06",
      "completion_date": "2017-02-01",
      "has_results": false,
      "last_update_posted_date": "2017-04-28",
      "last_synced_at": "2026-05-22T09:05:36.718Z",
      "location_count": 1,
      "location_summary": "Tampa, Florida",
      "locations": [
        {
          "city": "Tampa",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01883648"
    },
    {
      "nct_id": "NCT05738486",
      "title": "A Study of Different Donanemab (LY3002813) Dosing Regimens in Adults With Early Alzheimer's Disease (TRAILBLAZER-ALZ 6)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Alzheimer's Disease",
        "Dementia",
        "Brain Diseases",
        "Central Nervous System Diseases",
        "Nervous System Diseases",
        "Neurodegenerative Diseases",
        "Neurocognitive Disorders",
        "Mental Disorders"
      ],
      "interventions": [
        {
          "name": "Donanemab",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Dexamethasone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "60 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "60 Years to 85 Years"
      },
      "enrollment_count": 1175,
      "start_date": "2023-02-28",
      "completion_date": "2027-05",
      "has_results": true,
      "last_update_posted_date": "2025-11-14",
      "last_synced_at": "2026-05-22T09:05:36.718Z",
      "location_count": 43,
      "location_summary": "Chandler, Arizona • Irvine, California • Long Beach, California + 38 more",
      "locations": [
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Irvine",
          "state": "California"
        },
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "Sherman Oaks",
          "state": "California"
        },
        {
          "city": "Atlantis",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05738486"
    }
  ]
}